Lecture 25 - Biological Therapy for Respiratory Diseases Flashcards
Define biological therapy
List a few examples
Use of:
• Living organisms
• Living organism-derived products
• Lab produced versions
Examples:
• Immunotherapy: vaccines, bacteria
• mAbs
Describe the use of nucleotide sequences in biological therapy
Used as: Antisense oligonucleotides
e.g. Formvirisen
• Marketed for CMV and ApoB
What are exosomes?
Vesicles released by a cell via exocytosis
How can exosomes be used therapeutically?
Exosomes can be engineered to contain desired components for delivery to cells:
• Introduction of nucleic acids via Exoporesis
• Small molecule loading
Particularly useful in administration of highly charged molecules that normally cannot cross plasma membranes
Outline the generation of mAbs
- Spleen cells from antigen challenged mice + myeloma cells
- Membranes forced to fuse with PEG
- HAT kills off myeloma cells that did not fuse
- Spleen cells are now immortal hybridomas
- Screening to look for the mAb specificity of interest
When was the generation of mAbs discovered?
Who designed this process?
Milstein & Köhler, 1975
When were mAbs first humanised?
1997
When were human mAbs first produced?
Describe how they were produced
2002 - Adalimumab (anti-TNF)
Generated from spleen cells of transgenic mice (have complete human Ig genes)
Describe therapeutic use of novel protein scaffold technology
*
What are recombinant proteins?
Give an example of therapeutic use of R.P.s
Recombinant proteins:
• Proteins derived from recombinant DNA
Recombinant DNA:
• DNA formed by laboratory methods of genetic recombination (such as molecular cloning) to bring together genetic material from multiple sources
• Creates sequences that would not otherwise be found in biological organisms
Therapeutic use:
• Recombinant GM-CSF in PAP (pulmonary alveolar proteinosis)
What is pulmonary alveolar proteinosis (PAP)?
Describe the mechanism, pathology, symptoms and murine model
Accumulation of surfactant in the alveoli
Mechanism:
• Loss of GM-CSF activity
• Reduced macrophage and PMN clearance of surfactant in the alveoli
Pathology:
• Alveolar oedema
• Impaired gas exchange
Symptoms:
• Dyspnoea and cough
GM-CSF -/- mice:
• Exhibit PAP like disease
Observation in PAP individuals:
• Anti-GMCSF autoantibodies
• Can PAP in mice with infusion of these Abs
How has PAP been treated in the past?
How could it be treated now?
Past:
• Lung lavage
Novel therapy:
• Administration of recombinant GM-CSF
Outline cell therapy for respiratory disease
Mesenchymal stem cells
Action:
• Tissue repair
• Anti-inflammatory effects
Release:
• IL-10
• TGF-β
• IL-6
Outline vaccine / adjuvant therapy for respiratory disease
What is the rationale?
Give examples and challenges
Vaccination against viruses that exacerbate COPD and asthma
Vaccines:
• Influenza vaccine
• RSV
• Rhinovirus
NB There are many serotypes for these viruses, so vaccination is challenging
Describe cytokine targeting of respiratory disease
e.g. In severe asthma
• Not controlled by LABA/ICS
Lebrikizumab
• anti-IL-13 mAb
• Prevents IL-13 from binding to receptor subunit IL-4Rα
IL-13 role in asthma: • IgE class switching • Macrophage stimulation • Smooth muscle stimulation • Differentiation of respiratory epithelium into goblet cells • Activation of fibroblasts